Authors: María Concepción LópezCarrizosa Pilar María SamperOts Aurora Rodríguez Pérez
Publish Date: 2010/10/01
Volume: 12, Issue: 8, Pages: 568-573
Abstract
This was a prospective nonrandomised study in which 26 patients with solid tumours and confirmed bone metastases were treated with ZA 4 mg every 3–4 weeks for 24 months or until a skeletalrelated event SRE was observed Serum CTX levels were determined at baseline and 6 12 18 and 24 months after study initiation SRE were evaluated using bone scintigraphyStudy participants had prostate 50 breast 31 lung 11 or bladder 8 tumours Mean age was 69 range 52–84 years and 65 men At baseline overall mean CTX levels were 56247 ± 30517 pg/dl Patients who showed disease progression during the study period showed significantly higher CTX levels at baseline and after 18 months of ZA treatment than patients who did not progress p = 0040 and p = 0006 respectively Patients with ≥5 bone metastases at diagnosis had significantly higher CTX levels after 18 months of ZA treatment than patients with 5 bone metastasis p = 0001 Similarly at 12 and 18 months patients without SRE had significantly lower CTX levels than patients in whom a SRE was observed p = 0005 and p = 0001 respectively
Keywords: